Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
A2BR
Checkpoint inhibitor
NK cell
Oral squamous cell carcinoma
PD-L1
Journal
PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
06
2023
accepted:
28
07
2023
medline:
5
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Adenosine promotes anti-tumor immune responses by modulating the functions of T-cells and natural killer (NK) cells in the tumor microenvironment; however, the role of adenosine receptors in the progression of oral squamous cell carcinoma (OSCC) and its effects on immune checkpoint therapy remain unclear. In this study, we obtained the tumor tissues from 80 OSCC patients admitted at the Shandong University Qilu Hospital between February 2014 and December 2016. Thereafter, we detected the expression of adenosine 2b receptor (A2BR) and programmed death-ligand 1 (PD-L1) using immunohistochemical staining and analyzed the association between their expression in different regions of the tumor tissues, such as tumor nest, border, and paracancer stroma. To determine the role of A2BR in PD-L1 expression, CAL-27 (an OSCC cell line) was treated with BAY60-6583 (an A2BR agonist), and PD-L1 expression was determined using western blot and flow cytometry. Furthermore, CAL-27 was treated with a nuclear transcription factor-kappa B (NF-
Identifiants
pubmed: 37663280
doi: 10.7717/peerj.15922
pii: 15922
pmc: PMC10474825
doi:
Substances chimiques
B7-H1 Antigen
0
BAY 60-6583
0
CD274 protein, human
0
NF-kappa B
0
prolinedithiocarbamate
135467-92-4
Receptors, Adenosine A2
0
Adenosine A2 Receptor Antagonists
0
Banques de données
figshare
['10.6084/m9.figshare.23266277.v1']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15922Informations de copyright
©2023 Wang et al.
Déclaration de conflit d'intérêts
The authors declare that there are no competing interests.
Références
Front Pharmacol. 2022 Jun 01;13:908882
pubmed: 35721189
Cancer Lett. 2023 Apr 28;560:216143
pubmed: 36958695
Cancers (Basel). 2023 Apr 02;15(7):
pubmed: 37046787
Clin Exp Metastasis. 2020 Apr;37(2):283-292
pubmed: 32020377
Inflamm Res. 2022 Nov;71(10-11):1203-1212
pubmed: 36064866
Int J Mol Sci. 2022 Aug 16;23(16):
pubmed: 36012461
Cell Biol Int. 2022 May;46(5):806-818
pubmed: 35128752
Eur J Med Chem. 2022 Jan 5;227:113907
pubmed: 34695776
Hemasphere. 2022 Oct 26;6(11):e794
pubmed: 36325271
J Immunol. 2022 Jul 15;209(2):401-411
pubmed: 35777852
Front Immunol. 2022 Jul 11;13:935957
pubmed: 35898506
Cancers (Basel). 2020 Oct 07;12(10):
pubmed: 33036368
Semin Cancer Biol. 2020 Apr;61:71-83
pubmed: 31542510
Trends Immunol. 2022 Sep;43(9):757-775
pubmed: 35965153
Int J Mol Sci. 2022 Dec 06;23(23):
pubmed: 36499710
Front Immunol. 2021 Jul 08;12:652054
pubmed: 34305889
Front Immunol. 2020 Jun 30;11:1387
pubmed: 32695120
J Immunother Cancer. 2022 Feb;10(2):
pubmed: 35135866
PeerJ. 2023 Feb 16;11:e14824
pubmed: 36811004
Clin Exp Med. 2023 Jul;23(3):553-567
pubmed: 36109471
Int J Mol Sci. 2020 Nov 11;21(22):
pubmed: 33187137
Cancers (Basel). 2023 Apr 16;15(8):
pubmed: 37190251
Int J Mol Sci. 2021 Jul 15;22(14):
pubmed: 34299203
Leukemia. 2020 Oct;34(10):2708-2721
pubmed: 32269319
Mol Cancer. 2021 May 29;20(1):80
pubmed: 34051805
Sci Transl Med. 2023 Mar 8;15(686):eabl4414
pubmed: 36888695
Exp Ther Med. 2021 Apr;21(4):340
pubmed: 33732313
Front Immunol. 2022 Mar 21;13:837230
pubmed: 35386701
Int J Mol Sci. 2021 May 12;22(10):
pubmed: 34066087
Front Immunol. 2023 Apr 28;14:1163585
pubmed: 37187740
Br J Cancer. 2020 May;122(11):1686-1694
pubmed: 32238919
Int J Mol Sci. 2023 May 17;24(10):
pubmed: 37240219